Healthcare Services Group, Inc. (HCSG) Q2 2025 Earnings Call Transcript — Neutral
HCSG Seeking Alpha — July 23, 2025Healthcare Services Group, Inc. (NASDAQ:HCSG ) Q2 2025 Earnings Conference Call July 23, 2025 8:30 AM ET Company Participants Matthew J. McKee - Chief Communications Officer Theodore Wahl - President, CEO & Director Vikas Singh - Executive VP & CFO Conference Call Participants Albert J.
Trustmark Corporation (TRMK) Q2 2025 Earnings Conference Call Transcript — Neutral
TRMK Seeking Alpha — July 23, 2025Trustmark Corporation (NASDAQ:TRMK ) Q2 2025 Earnings Call July 23, 2025 9:30 AM ET Company Participants Duane Arthur Dewey - President, CEO & Director F. Joseph Rein - Executive VP & Director of Corporate Strategy George T.
Dovish Fed comments suggest FOMC intrigue, gold will challenge $3,500 soon – Commerzbank's Nguyen — Positive
AAAU BAR CRZBF CRZBY DBP DGL GLD GLDM IAU OUNZ SGOL UGL Kitco — July 23, 2025Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.
GE Vernova (NYSE:GEV) shares surged almost 15% after the energy company's second quarter earnings beat expectations, driven by strong performance in its Power and Electrification segments. Earnings per share (EPS) of $1.86 were significantly ahead of estimates of $1.50.
Dream Finders Homes (DFH) Moves 13.0% Higher: Will This Strength Last? — Positive
DFH Zacks Investment Research — July 23, 2025Dream Finders Homes (DFH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Thermo Fisher shares surge after Q2 beat, boosted by product launches — Positive
TMO Proactive Investors — July 23, 2025Shares of Thermo Fisher Scientific Inc (NYSE:TMO, ETR:TN8) jumped nearly 12% on Wednesday morning after the company reported second-quarter results that topped Wall Street estimates, fueled by strong demand across its life sciences and diagnostics segments. The company posted revenue of $10.86 billion, surpassing analysts' expectations of $10.69 billion and marking a 3% year-over-year increase.
Moody's Q2 Earnings Beat Estimates, Revenues & Expenses Rise Y/Y — Positive
MCO Zacks Investment Research — July 23, 2025MCO registers strong y/y earnings and revenue growth in Q2, though rising expenses and mixed segment results weigh.
Rising Cash Flows Make These 4 Stocks Worth Choosing Now — Positive
CPRX GAMB ORN STKL Zacks Investment Research — July 23, 2025CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma — Neutral
HALO PRNewsWire — July 23, 2025DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma," said Dr. Helen …
Forget PLTR: These 3 AI Stocks Have 5x Potential — Negative
ACMR LSRCY SERV 24/7 Wall Street — July 23, 2025Most AI stocks at the moment are at nosebleed valuations.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings — Neutral
FTRE PRNewsWire — July 23, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fortrea Holdings Inc. ("Fortrea" …
WOOF INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In WOOF To Contact Him Directly To Discuss Their Options — Neutral
WOOF PRNewsWire — July 23, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Petco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Petco Health and Wellness …
T Beats Q2 Earnings Estimates on Higher Revenues, Solid Demand — Positive
T Zacks Investment Research — July 23, 2025T tops Q2 estimates with solid wireless growth, strong cash flow and momentum in fiber and 5G investments.
Compared to Estimates, First Community (FCCO) Q2 Earnings: A Look at Key Metrics — Positive
FCCO Zacks Investment Research — July 23, 2025The headline numbers for First Community (FCCO) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
INVESTOR ALERT: Investigation of Nutex Health Inc. (NUTX) Announced by Holzer & Holzer, LLC — Neutral
NUTX GlobeNewsWire — July 23, 2025ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) complied with federal securities laws. On July 22, 2025, Blue Orca Capital released a report regarding, among other things, Nutex's reimbursement rates. Following this news, the price of the Company's stock dropped.
Earnings push Fiserv's stock toward its worst year since 2008. Here's what worries Wall Street. — Negative
FI Market Watch — July 23, 2025The fintech company's disappointing growth trends in its merchant business have one analyst concerned that competition is dogging the Clover brand.
High Yielding Dividend Stocks Creating American Energy Independence — Positive
ENB EPD ET MPLX WES 24/7 Wall Street — July 23, 2025The Trump Administration policy of US energy independence, combined with the exponentially increased demands for electric power to fuel AI and data centers, is fueling increases in domestic oil and gas production due to the unreliability of wind and solar power.
GEV Rallies Strong While ENPH Posts Soft Guidance, FI Sells on Earnings Beat — Neutral
ENPH FI GEV Schwab Network — July 23, 2025GE Vernova (GEV) powered its year-to-date rally to over 80% after a strong showing in earnings. Diane talks about how A.I. prospects are fueling optimism. Meanwhile, Enphase Energy (ENPH) sold off on soft guidance as macro headwinds affect the solar industry. Diane also talks about why Fiserv (FI) is selling off more than 20% despite posting an earnings beat.
America Movil Q2 Earnings Miss, Revenues Up Y/Y on Business Momentum — Positive
AMX Zacks Investment Research — July 23, 2025AMX swings to profit in Q2 2025 with surging service revenues and 1.7M new wireless subscribers but misses EPS estimates.
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings? — Positive
MRK Zacks Investment Research — July 23, 2025Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.